Evidence map›Paper›PMID 42726196›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Protein O-Glycosylation Shapes Lymphatic Endothelia and Lymph Node Macrophage Populations.

Jasmin Frey, Annkathrin Ratter, Finn Brigger, Louie Cielen, Pascal Kunz, Ea Tulin, Kinga Mikos, Lothar Dieterich, Marco D'Addio, Cornelia Halin and 2 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jasmin FreyInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-7029-7848
Annkathrin RatterInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0009-0001-4059-3096
Finn BriggerInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0009-0006-7634-1137
Louie CielenInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0009-0006-6677-5476
Pascal KunzInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-2490-0279
Ea TulinDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8889-5317
Kinga MikosInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0009-0001-2717-8189
Lothar DieterichInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-7908-5710
Marco D'AddioInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-7339-8043
Cornelia HalinInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-7899-2850
Richard D CummingsDepartment of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8918-5034
Vivianne I OttoInstitute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1157-0186

Funding

Novartis Stiftung für Medizinisch-Biologische Forschung (Novartis Foundation for Medical-Biological Research) 22C-234OPO-Stiftung (OPO-Foundation) 2018-0048OPO-Stiftung (OPO-Foundation) 2020-0018OPO-Stiftung (OPO-Foundation) 2025-0009Vontobel-Stiftung (Vontobel Foundation) 0264/2024
6 · The paper itself

Abstract

Endothelial cells were among the first cells identified to have a surface glycocalyx, but its functions are still elusive. Within the glycocalyx are many glycoproteins whose O-glycosylation is partly regulated by Cosmc, an essential chaperone for functional activity of T-synthase that adds galactose to O-glycans initiating their elongation. Using mice with inducible deletion of either Cosmc (C1Galt1C1) or the sialyltransferase St3Gal-1 in lymphatic endothelial cells (LEC), we discovered that loss of elongated O-glycans is accompanied by major changes in glycoprotein composition, including podoplanin, CD44, Lyve-1, and ICAM-1. These changes in the endothelial glycocalyx are sensed by adhesion molecules, such as Siglec-1, and lead to major changes in the size and phenotype of lymph node macrophage populations. Our findings demonstrate the crucial roles of O-glycosylation in regulating LEC functions and lymph node macrophage differentiation.

Indexed as

Endothelial CellsEndothelium, LymphaticLymph NodesMacrophagesAnimalsbeta-Galactoside alpha-2,3-SialyltransferaseCell DifferentiationGlycocalyxGlycoproteinsGlycosylationHyaluronan ReceptorsMembrane GlycoproteinsMembrane Transport ProteinsMiceMice, Inbred C57BLMice, Knockoutbeta-Galactoside alpha-2,3-SialyltransferaseCd44 protein, mouseCosmc protein, mouseGlycoproteinsHyaluronan ReceptorsLYVE1 protein, mouseMembrane GlycoproteinsMembrane Transport ProteinsMolecular ChaperonesPdpn protein, mousePodoplaninPolysaccharidesSialic Acid Binding Ig-like Lectin 1SialyltransferasesSiglec1 protein, mouseVesicular Transport Proteinscell surface glycoproteinsglycomelymphatic endotheliamacrophagesmurine lymph nodeO‐glycosylation

Identifiers

PMID42726196
PMCPMC13565275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.